Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $240.14 million. The enterprise value is $379.00 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, before market open.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 183.31 million shares outstanding. The number of shares has decreased by -0.61% in one year.
| Current Share Class | 183.31M |
| Shares Outstanding | 183.31M |
| Shares Change (YoY) | -0.61% |
| Shares Change (QoQ) | -21.79% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 58.60% |
| Float | 152.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.38 |
| Forward PS | 2.96 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.53 |
| EV / EBITDA | 106.58 |
| EV / EBIT | 307.63 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.82
| Current Ratio | 0.82 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | 33.00 |
| Debt / FCF | n/a |
| Interest Coverage | 0.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 0.34% |
| Return on Invested Capital (ROIC) | 0.53% |
| Return on Capital Employed (ROCE) | -4.65% |
| Revenue Per Employee | $1.23M |
| Profits Per Employee | -$7,631 |
| Employee Count | 122 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 0.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.77% in the last 52 weeks. The beta is 1.26, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -31.77% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 1.82 |
| Relative Strength Index (RSI) | 49.38 |
| Average Volume (20 Days) | 1,666,298 |
Short Selling Information
The latest short interest is 32.96 million, so 17.98% of the outstanding shares have been sold short.
| Short Interest | 32.96M |
| Short Previous Month | 32.39M |
| Short % of Shares Out | 17.98% |
| Short % of Float | 21.57% |
| Short Ratio (days to cover) | 21.93 |
Income Statement
In the last 12 months, HRTX had revenue of $149.69 million and -$931,000 in losses. Loss per share was -$0.01.
| Revenue | 149.69M |
| Gross Profit | 98.84M |
| Operating Income | 1.23M |
| Pretax Income | -931,000 |
| Net Income | -931,000 |
| EBITDA | 3.56M |
| EBIT | 1.23M |
| Loss Per Share | -$0.01 |
Full Income StatementBalance Sheet
The company has $40.63 million in cash and $176.74 million in debt, giving a net cash position of -$136.11 million or -$0.74 per share.
| Cash & Cash Equivalents | 40.63M |
| Total Debt | 176.74M |
| Net Cash | -136.11M |
| Net Cash Per Share | -$0.74 |
| Equity (Book Value) | -27.26M |
| Book Value Per Share | -0.18 |
| Working Capital | -47.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.15 million and capital expenditures -$1.39 million, giving a free cash flow of -$29.53 million.
| Operating Cash Flow | -28.15M |
| Capital Expenditures | -1.39M |
| Free Cash Flow | -29.53M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 66.03%, with operating and profit margins of 0.82% and -0.62%.
| Gross Margin | 66.03% |
| Operating Margin | 0.82% |
| Pretax Margin | -0.62% |
| Profit Margin | -0.62% |
| EBITDA Margin | 2.38% |
| EBIT Margin | 0.82% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.61% |
| Shareholder Yield | 0.61% |
| Earnings Yield | -0.38% |
| FCF Yield | -12.16% |
Analyst Forecast
The average price target for HRTX is $4.50, which is 243.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.50 |
| Price Target Difference | 243.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 15.19% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
HRTX has an Altman Z-Score of -10.46 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.46 |
| Piotroski F-Score | 3 |
